Log in using OpenID

Erythropoietin Drugs Market Expansion to be Persistent During 2018 – 2026

Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body. Erythropoietin drugs are developed in vitro by extracting the erythropoietin from the human body and developing it through the use of recombinant
Erythropoietin Drugs Market Set for Rapid Growth
And Trend by 2026
Erythropoietin Drugs Market — Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2018-2026
Market Overview
Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body.
Erythropoietin drugs are developed in vitro by extracting the erythropoietin from the human body and
developing it through the use of recombinant DNA technology. Erythropoietin drugs are also used to
treat anemia induced from cancer, multiple myloma and HIV associated anemia. Recombinant DNA
technology has allowed researchers to develop synthetic forms of erythropoietin such as epoetin alfa,
epoetin beta, epoetin delta and epoetin omega. The erythropoietin drugs market has witnessed strong
adoption in the cancer and HIV associated anemia treatment. The erythropoietin alfa biosimilars have
gained significant traction in the past two years and the market will witness the introduction of new
biosimilars as the existing erythropoietin drugs undergo patent expiration.
Growing prevalence of Anemia and introduction of Biosimilar will drive market growth
As per the WHO report published in 2011, an estimated 800 million people are affected by Anemia
globally with large prevalence observed in Asia Pacific and African region. In U.S., the prevalence rate
for Anemia is 5.6% which is estimated to increase in the near future as the rate of cancer witnesses a
growing trend. According to the study conducted by India Spend, India has the highest prevalence of
Anemia worldwide with 10.6% of YLD’s caused due to disability. Factors such as poor sanitation
facilities, lack of healthy diet and poverty are responsible for high prevalence of Anemia in the country.
The erythropoietin drugs market has seen a dramatic shift from reference drugs to biosimilar with
major pharmaceutical companies such as Amgen, Novartis and Pfizer developing erythropoietin
biosimilar. The growth is accounted to the fact that biosimilar are relatively easier to develop and less
cost intensive which has increased the adoption rate.
Ask For a Sample Copy of This Business Report :
Introduction of new erythropoietin biosimilar will intensify the market competition
The key players in the erythropoietin drugs market are Amgen, GlaxoSmithKline, Pfizer, Johnson &
Johnson, Novartis, Biocon, Ranbaxy Laboratories and Teva Pharmaceutical ltd. Due to the high cost
associated with the development of innovator drugs and the patent expiration of the first erythropoietin
drug launched by Amgen, the major players in the market are introducing erythropoietin biosimilar in
the market with major focus on darbepoietin alfa drug.
Europe leads the market and Asia Pacific will witness significant growth
Europe is the largest market for erythropoietin drugs market with large patient pool, developed
healthcare infrastructure and better reimbursement scenario. The pharmaceutical companies continue to
introduce biosimilar in the region to compete against the reference drugs. The drug approval process is
less stringent as compared to North America which leads to fast approval of drugs. The mortality rate is
1.2 per 100,000 population for Anemia across Europe. North America is going to be an important
market for the erythropoietin drugs industry as the drugs under clinical trials get approval from FDA
and key drugs such as Epogen and Aranesp face patent expiration
Asia Pacific region is fastest growing erythropoietin drugs market, with countries such as India and
China showing lucrative growth. India has the highest prevalence of anemia in the world followed by
China. According to study conducted by Stanford University, an estimated180 million people suffer
from Anemia in central and eastern China with the old age population more prone to it. The market of
erythropoietin drugs will grow significantly as major pharmaceutical companies continue to expand the
drug manufacturing process in countries such as India, China and Japan. Factors such as less stringent
regulatory scenario and commercialization of erythropoietin biosimilars in the region will drive the
Erythropoietin Drugs Market forward.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
ravikiran298   documents Email
Health and Medicine
File Size
360 KB
Report inappropriate content